


Once more we feel that things are moving in our direction. And just in time for Christmas too! Thanks to a story by the redoubtable Kat Lay of the Guardian, we bring you news of not one, but two new antibiotics, gentle readers. Both Zoliflodacin and Gepotidacin have passed major trials and have been approved this very month by the US Food and Drug Administration. Always a major step in their progress to world-wide use.[1]
We will keep our bit short today. Kat’s excellent story is a lucid and succinct presentation of all you need to know-infection rates, strains, statistics and the marvellous groups of educated, open minded people who have worked so hard to get humanity to this stage. Suffice it to say you might wish to learn more about Global Antibiotic Research & Development Partnership (GARDP) who seem to be just the sort of people we have been hoping to have around in this crisis (thanks for that, Kat) So, go on-click.
Hardened fans of LSS and the antibiotics resistance community in general will be aware of our earlier thoughts on this aspect of the problem(LSS 19 2 24; 12 9 24) It is a genuine pleasure to see advances being made, and not just in STDs, after more than ten years of campaigning. The antibiotics crisis is not over yet; but compared with where we were about 2015, this feels better. So, although we are not going to let up, enough time has been bought to devote a little of it to another of our bêtes noires: the intractable mystery of mental illness and its causes. But this time, we think there’s hope there too. Don’t miss our next amazing blog.
[1https://www.theguardian.com/global-development/2025/dec/16/health-antibiotic-resistance-drugs-superbugs-sexually-transmitted-gonorrhoea
#antibiotic resistance #microbiology #health #medicine #bacteria #STD #GARDP























